Introduction
T-cell leukemia is caused by activation of several oncogenes including TAL1/SCL (hereafter referred to as TAL1), LMO2, MYC, HOX11, and more recently by mutations in NOTCH1 (Look, 1997; Ferrando et al., 2004; Weng et al., 2004) . We and others have shown that misexpression of Tal1 in the thymus alters thymocyte development by interfering with the expression of E47/HEB target genes including Rag1/2, Pre-Ta, CD4, CD5, CD3 and the TCRabchains (Herblot et al., 2000; O'Neil et al., 2001 O'Neil et al., , 2004 . Although Tal1 induces leukemia in mice, it does so after a long latency revealing that additional genetic events are required (Condorelli et al., 1996; Kelliher et al., 1996) . Analysis of the INK4A/ARF locus in human T-ALL patients has revealed frequent homozygous deletion of exon 2, the exon common to both p16 INK4A and p14 ARF genes (Hebert et al., 1994; Cayuela et al., 1995 Cayuela et al., , 1996 Drexler, 1998; Gardie et al., 1998; Ferrando et al., 2002) . Other T-ALL patients also exhibit alterations in the INK4A/ ARF locus that affect either p16 INK4A or p14 ARF only. Specifically, in some cases, T-ALL patients exhibit methylation of the p16 INK4A promoter, whereas others display specific loss of p14 ARF , as detected by loss of exon 1b (Batova et al., 1997; Drexler, 1998; Gardie et al., 1998) . Of TAL1-expressing T-ALL patients, 92% (13/14) have been shown to delete the shared exon 2, suggesting that loss of both p16 INK4A and p14 ARF may be required to cooperate with ectopic TAL1 activation (Ferrando et al., 2002) . Moreover, clinical studies have suggested that INK4A/ARF deletions are a poor prognostic indicator, highlighting the need for additional therapies to treat these T-ALL patients (Kees et al., 1997; Zhou et al., 1997; Harrison, 2001) .
To model the INK4A/ARF deletion in mice, and to determine the overall contribution of loss of p16
Ink4a and p19
Arf to Tal1-induced leukemia, we mated our tal1 transgenic mice to ink4a/arfÀ/À, p16 ink4a À/À, and p19 arf À/À mice, and generated cohorts of tal1/ink4a/ arf þ /À tal1/p16 ink4a þ /À and tal1/p19 arf þ /À mice. We observe disease acceleration in tal1/ink4a/arf þ /À mice and in tal1/p16 ink4a þ /À and tal1/p19 arf þ /À mice, providing genetic evidence that Tal1 cooperates with loss of either p16
Ink4a or p19 Arf to cause leukemia in the mouse. Our preleukemic studies reveal that in addition to its effects on thymocyte differentiation (O'Neil et al., 2004) , Tal1 expression stimulates entry into the cell cycle and thymocyte apoptosis in vivo. Interestingly, mice expressing a DNA-binding mutant of Tal1 exhibit blocks in thymocyte development (O'Neil et al., 2001 ), but do not show any changes in cell cycle. Hence, the ability to stimulate thymocyte proliferation appears dependent on the ability of Tal1 to bind DNA, and also appears to be independent of the effects of Tal1 on thymocyte differentiation. The S phase induction is associated with an increase in thymocyte apoptosis observed in preleukemic tal1 mice, but not in tal1/ink4a/arfÀ/À mice. Taken together, these studies suggest that Tal1 contributes to leukemogenesis by inhibiting differentiation, stimulating cell cycle entry and by activating an Ink4a/ Arf-dependent apoptotic pathway.
Results
ink4a/arf loss cooperates with Tal1 to induce T-cell leukemia in mice T-ALL patients with TAL1 activation frequently display homozygous loss of exon 2 of the INK4A/ARF locus, suggesting that loss of both p16
INK4a and p14 ARF (p19 Arf in mice) are required (Ferrando et al., 2002) . To determine if ink4a/arf loss cooperates with Tal1 to induce leukemia in the mouse, we mated our tal1 transgenic mice to ink4a/arfÀ/À mice and established a cohort of tal1/ink4a/arf þ /À mice. Tal1 transgenic mice develop T-cell lymphoblastic leukemia with a median survival period of 350 days (Kelliher et al., 1996) . However, tal1/ink4a/arf þ /À mice develop disease rapidly with a median survival period of 168 days (Figure 1 ). Additionally, there is a highly significant increase in disease penetrance in the tal1/ink4a/arf þ /À mice compared to that in tal1 mice (Po0.0001). Only 28% of tal1 mice on a wild-type background develop T-cell lymphoblastic leukemia, whereas 100% of tal1/ ink4a/arf þ /À mice develop disease. The tumors that arise in tal1/ink4a/arf þ /À mice are identical to those observed in tal1 mice and express both CD4 and CD8 or CD8 alone (Table 1) (Kelliher et al., 1996; O'Neil et al., 2004) . Interestingly, 8/11 tal1/ink4a/arf þ /À tumors express high CD25 levels, a feature also observed in T-cell tumors induced by activated Notch1 (ShankCalvo and Kelliher, unpublished data) or Notch 3 (Bellavia et al., 2000) . ink4a/arf alterations are detected in mouse tal1/ink4a/ arf þ /À tumors As homozygous deletion of exon 2 of the INK4A/ARF locus is commonly observed in T-cell leukemia patients (Hebert et al., 1994; Cayuela et al., 1995 Cayuela et al., , 1996 , we examined our mouse tal1/ink4a/arf þ /À tumors for evidence of LOH using genomic PCR and Southern blotting. Tumor DNA was isolated and genomic PCR performed to examine the integrity of p16
Ink4a
-specific exon 1a, p19
Arf -specific exon 1b, and the shared exon 2 of the ink4a/arf locus. We detected low levels of exon 2 in 2/7 tumors examined, suggesting that the majority of cells in the tumor had undergone LOH (Figure 2a ). To confirm these findings, Southern blot analysis was performed on 18 tal1/ink4a/arf þ /À tumors. Tumor DNA was digested with the restriction enzyme Pst I, transferred to a membrane and hybridized with a cDNA probe containing part of exon 1a and exon 2. Five of eighteen (27%) tumors exhibited evidence of LOH, as the wild-type 9 kb fragment containing exon 2 was not detected in these tumors, indicating these tumors lose expression of both p16
Ink4a and p19 Arf ( Figure 2b and data not shown). The reduced levels of exon 2 observed in lanes 5 and 8 of the genomic PCR correspond to tumor DNA samples in lanes 2 and 5 of the Southern blot, respectively (Figure 2a and b) .
Southern blot analysis detects the presence of exon 1a (2.5 kb band) and exon 2 in the remaining tal1/ink4a/ arf þ /À tumors examined, suggesting that mutations or promoter methylation may affect expression of p16 Ink4a or p19
Arf in the remaining tumors ( Figure 2b ). To determine if methylation of the p16 ink4a promoter occurs in tal1/ink4a/arf þ /À tumors, we performed methylation-specific PCR. Genomic DNA isolated from the tumors was treated with sodium bisulfite, and methylated CpG islands were amplified with primers specific for both unmethylated and methylated region of the p16 ink4a promoter (Sharpless et al., 2001) . We find evidence of p16 ink4a methylation in 2 of 7 (28%) tal1/ ink4a/arf þ /À tumors examined, indicating that the methylation of the p16 ink4a promoter and the subsequent loss of p16
Ink4a expression contributes to Tal1-induced leukemia in the mouse (Figure 2c and data not shown).
Loss of either p16
Ink4a or p19 Arf cooperates with Tal1 to induce leukemia in mice Human T-ALL patients frequently display homozygous loss of the INK4A/ARF locus, but also demonstrate the Figure 1 Disease acceleration in tal1/ink4a/arf þ /À mice. KaplanMeier survival plot of tal1 and tal1/ink4a/arf þ /À mice is shown. The tal1 cohort consisted of n ¼ 64 animals, and the cohort of tal1/ink4a/arf þ /À mice consisted of n ¼ 27. Tarone-Ware statistical analysis demonstrates a highly statistically significant difference in survival between the tal1 transgenic mice and the tal1 transgenic mice on the ink4a/arf heterozygous background (Po0.0001).
Loss of p16
Ink4a or p19 Arf cooperates with Tal1/scl JA Shank-Calvo et al specific loss of p14 ARF or p16
INK4A
, indicating loss of either tumor-suppressor may contribute to T-cell leukemogenesis (Hebert et al., 1994; Cayuela et al., 1995 Cayuela et al., , 1996 Drexler, 1998; Gardie et al., 1998) . Similarly, analysis of our mouse tal1/ink4a/arf þ /À tumors suggested that loss of either p19
Arf or p16
Ink4a may contribute to disease development in the mouse. To determine the relative contribution of loss of the p16 Ink4a or p19 Arf tumor suppressor genes to Tal1-induced leukemia in the mouse, we mated the tal1 transgenic mice to p16 ink4a À/À or p19 arf À/À mice and generated cohorts of tal1/p16 ink4a þ /À (n ¼ 26) and tal1/p19 arf þ /À mice (n ¼ 28). Both the tal1/p16 ink4a þ /À and tal1/ p19 arf þ /À mice develop leukemia at an accelerated rate compared to tal1 mice on a wild-type background (Figure 3 ; Po0.00005 for tal1/p19
Arf þ /À and P ¼ 0.0132 for tal1/p16 ink4a þ /À mice). The difference in disease kinetics observed between tal1/p19
Arf þ /À and tal1/p16 ink4a þ /À mice was not statistically significant (P ¼ 0.0698). Although all mice developed T-cell leukemia, some differences in the tumor target cells were observed. In contrast to tal1 mice and tal1/ink4a/arf þ / À mice, where most of the tumors are CD4-and CD8-double positive (DP), fewer DP tumors were observed in the tal1/p19
Arf þ /À and tal1/p16 ink4a þ /À mice (Table 1 ) (Kelliher et al., 1996) . Differences in the expression of CD25 are also observed; the majority of tal1/ink4a/ arf þ /À tumors (10/11 or 91%) examined express CD25 whereas only 2/9 or 22% of tal1/p16 þ /À tumors express CD25, suggesting that a different target cell may be transformed in these mice.
Tal1 stimulates an increase in S phase cells Ink4a/arf loss in the tal1/ink4a/arf þ /À tumors suggests that ectopic expression of Tal1 may stimulate thymocyte proliferation in vivo and thereby trigger loss of the cell cycle inhibitor p16
Ink4a or the oncogene sensor p19 Arf . To determine if Tal1 expression alters the cell cycle, we performed in vivo-BrdU incorporation studies on preleukemic tal1 mice. To examine thymocyte cell cycle, wild-type and tal1 transgenic mice were injected intraperitoneally with BrdU, and following a 4 h rest, thymocytes were stained with anti-BrdU antibodies. In wild-type mice, 14.52% (71.4%) BrdU-positive thymocytes were detected. Interestingly, in the tal1 transgenic mice, 24.47% (72.8%) of cells were detected in S phase of the cell cycle (Po0.008) (Figure 4 ). This 70% increase in the percentage of thymocytes in S phase suggests that Tal1 expression may stimulate thymocytes to inappropriately enter the cell cycle.
S phase induction is dependent on a functional DNA-binding domain of Tal1
Inhibition of E2A activity has been associated with increased proliferation and with stem cell self-renewal capability (Iavarone et al., 1994; Peverali et al., 1994; Lasorella et al., 1996; Pagliuca et al., 2000) . Tal1 and the Tumors were stained with antibodies to CD3, CD4, CD8 and CD25 and analysed by flow cytometry. Tumors were considered positive if >10% of the tumor stained for that antibody.
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Ink4a or p19 Arf cooperates with Tal1/scl JA Shank-Calvo et al DNA-binding mutant of Tal1 (Tal1R188G;R189G) inhibit E2A transcriptional activity and induce leukemia in mice (O'Neil et al., 2001 (O'Neil et al., , 2004 . Thus, the S phase induction may be mediated by the ability of Tal1 (and the DNA-binding mutant of Tal1) to inhibit the transcriptional activity of E47/HEB. Alternatively, the ability to stimulate the cell cycle may reflect the ability of the Tal1/E47 or HEB heterodimers to transactivate the expression of genes capable of stimulating proliferation. In order to distinguish between these possibilities, we compared thymocyte proliferation in preleukemic tal1 transgenic mice to that observed in tal1R188G;R189G transgenic mice. In contrast to the 24.47% (72.8%) cells in S phase observed in tal1 mice, tal1R188G;R189G mice contain 15.2% (72.1%) cells in S phase of the cell cycle, similar to the 15.5% (71.5%) observed in wildtype littermates ( Figure 5) . Thus, the ability of Tal1 to stimulate the cell cycle appears dependent on a functional DNA-binding domain and suggests that Tal1/E47 or HEB heterodimers stimulate S phase by influencing gene expression. Thus, although the DNAbinding mutant of Tal1R188G;R189G functions like an Id and interacts with and inhibits E protein function, it appears unable to affect cell cycle control.
Tal1 stimulates thymocyte apoptosis in vivo that is p19
Arf dependent Oncogenes stimulate inappropriate entry into the cell cycle and activate a protective apoptotic pathway that involves activation of the p19
Arf -p53 proteins (Evan et al., 1992; Rao et al., 1992; Zindy et al., 1998) . Consistently, BrdU analysis demonstrates that the S phase induction observed in preleukemic tal1 thymocytes is accompanied by an increase in subG 1 cells (Figure 6 ). Although the percentage of apoptotic thymocytes was variable and ranged from a 5 to 10-fold increase in subG 1 cells, the percentage of subG1 thymocytes consistently correlated with the increase in S phase cells observed. To test whether Tal1-associated apoptosis requires an intact ink4a/arf locus, we examined thymocyte proliferation/apoptosis in an ink4a/ arfÀ/À genetic background. In contrast to Tal1 expression in a wild-type or ink4a/arf þ /À background that To examine the integrity of the ink4a/arf locus, genomic DNA was isolated from tal1/ink4a/arf þ /À tumors and screened for the presence of exon 1a, exon 1b and exon 2 using PCR. (b) LOH in tumors from tal1/ink4a/arf þ /À mice. To further analyse the status of exon 2, genomic DNA from tal1/ink4a/arf þ /À tumors was digested with Pst I, transferred to a membrane, and probed with cDNA probe corresponding to exon 1a and exon 2. (c) Methylation of p16 ink4a promoter in a subset of tal1/ink4a/arf þ /À tumors. To analyse the methylation status of the p16 ink4a promoter, bisulfitetreated tal1/ink4a/arf þ /À tumor DNA was amplified using primers specific for the p16 ink4a methylated promoter and p16 ink4a unmethylated promoter as described in (Sharpless et al., 2001) . Figure 3 Disease acceleration in tal1/p16 ink4a þ /À and tal1/p19 arf þ /À mice. Kaplan-Meier survival plot of tal1, tal1/ink4a/arf þ /À, tal1/ p16 ink4a þ /À and tal1/p19 arf þ /À mice is shown. The cohort of tal1 was n ¼ 64 animals, tal1/ink4a/arf þ /À was n ¼ 27 animals, tal1/ p16 ink4a þ /À was n ¼ 26 animals and tal1/p19 arf þ /À was n ¼ 28 animals. Tarone-Ware statistical analysis demonstrates a highly statistically significant difference in survival between the tal1 transgenic mice and the tal1 transgenic mice on the p16 ink4a or p19 arf heterozygous background (Po0.0001 for tal1 compared to tal1/ p19 arf þ /À, and Po0.0092 for tal1 compared to tal1/p16 ink4a þ /À).
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Ink4a or p19 Arf cooperates with Tal1/scl JA Shank-Calvo et al results in 12% subG 1 cells, only 2.7% of thymocytes were detected in the subG 1 population when Tal1 was expressed on a ink4a/arfÀ/À background ( Figure 6 ). However, the increase in S phase cells is unaffected by an Ink4a/Arf deficiency as increases in S phase cells were observed in both the tal1/ink4a/arf þ /À and tal1/ink4a/ arfÀ/À mice ( Figure 6 ). Therefore, the ability of Tal1 to stimulate S phase entry in the preleukemic phase of the Figure 5 Increase in S phase cells is observed in tal1 transgenic mice but not in mice expressing a DNA-binding mutant of Tal1 (Tal1R188G;R189G). To determine if DNA-binding domain is essential for the increase in S phase cells, in vivo BrdU-incorporation experiments were performed on wild type, tal1 transgenic, and tal1R188G;R189G transgenic mice. Mice were injected i.p. twice with 1 mg of BrdU, and following a 4 h rest, thymocytes were stained with antibodies to BrdU and analysed by flow cytometry. Tal1(R188G;R189G) mice have decreased levels of BrdU-positive cells compared to tal1 thymocytes (P ¼ 0.02). Three wild type, three tal1 and three tal1R188G;R189G transgenic animals were analysed. 
Ink4a or p19 Arf cooperates with Tal1/scl JA Shank-Calvo et al disease is not influenced by ink4a/arf loss, suggesting it is independent of the cell cycle inhibitor p16
Ink4a . In contrast, induction of apoptosis associated with Tal1 activation appears dependent on the presence of an ink4a/arf allele.
Activation of the Notch1 and Wnt5b pathways in preleukemic tal1 thymocytes To identify how Tal1 activation may result in thymocyte proliferation, we used gene expression profiling to compare genes activated/repressed in Tal1 expressing thymocytes compared to littermate controls. Consistent with the perturbed thymocyte development observed in preleukemic tal1 mice and with our previous microarray experiments performed on tal1 DP thymocytes (O'Neil et al., 2004) , we found the expression of multiple E47/ HEB target genes repressed in ta1l thymocytes including Rag1/2, Pre-Ta, CD5, CD6, CD4 (Table 2) .
Interestingly, and consistent with the S phase induction, analysis of Tal1-regulated genes revealed activation of the Notch and Wnt receptor pathways. Specifically, Wnt5b and its downstream target gene, c-Myc, appeared upregulated in tal1 thymocytes compared to littermate controls (Table 2) (He et al., 1998) . Real-time Figure 6 Thymocyte apoptosis in tal1 but not tal1/ink4a/arfÀ/À thymocytes. To determine if Tal1 activates the p19 Arf -p53 pathway, in vivo BrdU-incorporation analyses were performed as described on wild-type, tal1, tal1/ink4a/arf þ /À and tal1/ink4a/arfÀ/À mice and analysed by flow cytometry. The increase in S phase cells was accompanied by an increase in subG1 cells, and this Tal1-mediated increase in subG1 cells is not observed in the absence of the ink4a/arf allele. A representative of three independent experiments is shown. (Staal and Clevers, 2005) , and Wnt activation has also been associated with blast crisis chronic myelogenous leukemia patients (Jamieson et al., 2004) . Additionally, evidence of Notch 1 activation was also detected in preleukemic tal1 thymocytes with increased expression of the Notch 1 target genes, Deltex, CD25, and Hes1, in preleukemic tal1 thymocytes (Table 2 and Figure 7) . Thus, the Tal1-induced thymocyte differentiation arrest may be alleviated by activation of the Wnt and/or Notch 1 receptor pathways, raising the possibility that these receptors/pathways may be mutated in mouse tal1 tumors and in T-ALL patients. Consistently, Notch1
mutations that result in deletion or truncation of the PEST domain are detected in 72% of our spontaneous mouse tal1 tumors (O'Neil et al., 2005) and mutations in the PEST domain and heterodimerization domains of Notch 1 are observed in human T-ALL (Weng et al., 2004) . Moreover, when Notch signaling is inhibited via treatment with the g-secretase inhibitors, mouse tal1 tumors and human T-ALL cell lines undergo G 1 arrest, demonstrating that Notch 1 activation provides proliferative signals in the context of Tal1 activation (O'Neil et al., 2005) .
Discussion
We and others have shown that Tal1 expression perturbs thymocyte development by interfering with the expression of E47/HEB target genes (Herblot et al., 2000; O'Neil et al., 2004) . Although Tal1 has been implicated in the proliferation of hematopoietic precursors (Green et al., 1991; Condorelli et al., 1997; Valtieri et al., 1998) , this study suggests that Tal1 also stimulates cell cycle entry in preleukemic thymocytes. The S phase induction observed in tal1 thymocytes during the preleukemic phase of the disease is accompanied by an increase in apoptosis that appears p19 Arfdependent. Thus, ectopic expression of Tal1 shares features with deregulated c-Myc, in that both proteins inhibit differentiation and are capable of stimulating the cell cycle and inducing apoptosis in vivo (Coppola and Cole, 1986; Evan et al., 1992; Eischen et al., 1999) .
Independent of its effects on thymocyte differentiation, Tal1 stimulates the cell cycle and this appears to be an effect of the Tal1/E47 or HEB heterodimers on transcription, as no increase in S phase cells is observed in mice expressing a DNA-binding mutant of Tal1. Although it remains unclear precisely how the increase in S phase cells is mediated by Tal1, our genetic studies in the mice reveal that Tal1 does not require the presence of an intact ink4a/arf locus to stimulate cell cycle during the preleukemic phase of the disease. Analysis of gene expression profiles influenced by Tal1 suggests that the cell cycle effects may involve activation of the Wnt and/or the Notch 1 receptor pathways. We find Wnt5b, Myc, Deltex, Hes1 and CD25a expression induced in preleukemic tal1 thymocytes compared to littermate controls. Thymocyte differentiation arrest induced by Tal1 expression and E47/HEB inhibition may stimulate Wnt or Notch 1 activation to rescue thymocyte precursors from the developmental arrest. Notch and/or Wnt activation may then result in sustained c-Myc expression and a corresponding increase in S phase cells in the preleukemic tal1 thymus. Consistent with this model, Em-myc transgenic mice exhibit similar increases in the percentage of S phase cells, and S phase induction is accompanied by apoptosis (Baudino et al., 2003) . The increased cell cycle activity in the preleukemic tal1 thymus results in apoptosis that is ink4a/arf-dependent, suggesting that Tal1 triggers the p19Arf-p53 apoptotic pathway. To assay CD25 levels, wild-type and tal1 premalignant thymocytes were stained with anti-CD25-PE, fixed and analysed by flow cytometry. A representative of three independent experiments is shown.
Loss of p16
Ink4a or p19 Arf cooperates with Tal1/scl JA Shank-Calvo et al However, mice expressing a DNA-binding mutant of Tal1 develop disease, which questions the overall biological significance of the effects of Tal1 on the cell cycle (O'Neil et al., 2001) . We speculate that the inappropriate cell cycle entry and apoptosis associated with Tal1 expression in vivo may provide an additional selective pressure to disrupt the ink4a/arf locus. This hypothesis predicts that ink4a/arf alterations would be observed at greater frequencies in tumors derived from tal1 transgenic mice than in tumors derived from the DNA-binding mutant mice. Disruption of the ink4a/arf locus is an important genetic event in Tal1-induced leukemia with alterations of both p16
Arf observed in mouse tal1/ink4a/arf þ /À tumors. Unlike the published studies on Em-myc/ink4a/arf þ /À mice, all of which undergo LOH (Eischen et al., 1999) , 27% (5/ 18) of the tal1/ink4a/arf þ /À tumors examined exhibit LOH and an additional 28% (2/7) of tumors exhibit methylation of the p16 ink4a promoter. We provide genetic evidence that loss of either p16
Ink4a or p19 Arf cooperates with Tal1 expression to induce T-cell leukemia in mice. Both tal1/p16 ink4a þ /À and tal1/p19 arf þ /À mice exhibit disease acceleration compared to tal1 mice on a wildtype background. Studies of leukemic patients suggest that INK4A/ARF loss is a poor prognostic indicator of ALL, and consistent with these observations, tal1/ink4a/ arf þ /À, tal1/p16 ink4a þ /À and tal1/p19 arf þ /À mice rapidly develop disease (Kees et al., 1997; Zhou et al., 1997; Harrison, 2001) . Importantly, 100% of tal1/ink4a/ arf þ /À mice develop T-cell leukemia, making this model useful for testing the sensitivity of these mice to current therapies and for the development of new therapeutics aimed at those T-ALL patients who express TAL1 and delete INK4A/ARF.
Materials and methods
Mice and tumor cell culture Proximal lck-tal1 mice and mut tal1 R188G;R189G have been described previously (Kelliher et al., 1996; O'Neil et al., 2001) . Ink4a/arf null, p16 ink4a À/À and p19 arf À/À mice have been described previously (Serrano et al., 1996; Kamijo et al., 1997; Sharpless et al., 2001) and were obtained from the Mouse Models of Human Cancers Consortium (MMHCC). Cohorts of tal1/ink4a/arf þ /À (n ¼ 27), tal1/p16 ink4a þ /À (n ¼ 26), and tal1/p19 arf þ /À (n ¼ 28) mice were established and monitored daily for signs of disease. Kaplan-Meier analysis was performed on tal1/ink4a/arf þ /À mice, tal1/p16 ink4a þ /À mice, and tal1/p19 arf þ /À mice and compared to tal1 mice on a wildtype background. All mice were maintained on a FVB/N genetic background.
Flow cytometry
Primary tumor cells were stained with PE-conjugated antimouse Ly-2 (CD8), FITC-conjugated L3T4 (CD4) and PEconjugated CD25 antibodies (BD Pharmingen, San Diego, CA, USA), and analysed using flow cytometry. For the in vivo bromodoxyuridine (BrdU)-incorporation assays, 4-6-week-old tal1, mut tal1R188G;R189G, tal1/ink4a/arf þ /À, and tal1/ ink4a/arfÀ/À mice were injected intraperitoneally with 1 mg BrdU and allowed to rest for 3 h. The mice were injected again with 1 mg of BrdU and allowed to rest for an additional 1 h. Thymocytes were isolated and 2 Â 10 6 cells were stained with CD4-FITC and CD8-PE antibodies. The thymocytes were then fixed, permeabilized and stained with APC-conjugated anti-BrdU antibody and 7-amino-actinomycin D (7-AAD) as described in APC BrdU Flow kit (BD Pharmingen). Values are provided as mean7standard deviation, and P-values are from Student's t-test analysis.
Real-time PCR
Wnt5b real-time primer sequences were obtained from Georg A Holla¨nder (5 0 -GGCATTGGGATGGGTTGAGG-3 0 and 5 0 -GGAGTTGGCGTCAGTCAGCAG-3 0 ). Primers for c-Myc (5 0 -CTGTTTGAAGGCTGGATTTCC-T-3 0 and 5 0 -GTCGT GGCTGTCTGCGG-3 0 ), Deltex (5 0 -TGCCTGGTGGCCAT GTACT-3 0 and 5 0 -GACACTGCAGGCTGCCATC-3 0 ), and Hes1 (5 0 -AAGACGGCCTCTGAGCACA-3 0 and 5 0 -CCTTC GCCTCTTCTCCATGAT-3 0 ) were designed using Primer Express (Applied Biosystems). Relative quantities of mRNA expression were analysed using QRT-PCR in the presence of SYBR green (Applied Biosystems ABI Prism 7300 Sequence Detection System, Applied Biosystems). For the normalization of each sample, the expression level of the gene was divided by that of b-actin. The relative expression level was determined by comparing the normalized value (/b-actin) to that in the reference sample (another normal tissue) included in the same reaction.
Microarray analysis
Thymocytes were pooled from four age-matched (4 weeks) wild-type and tal1 transgenic mice, RNA extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA), and purified using Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA, USA). RNA was hybridized to Affymetrix Mouse Genome 430A 2.0 arrays (Affymetrix, Santa Clara, CA, USA). The raw data was normalized, log transformed and the set of genes showing statistically significant differential expression was obtained. The analysis was performed with the help of R language scripts of the Bioconductor package and Rosetta Resolver.
